Abstracts tagged "Economics"

Abstract Number: 145 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis
Zheng-Yi Zhou¹, Jenny Griffith², Arijit Ganguli², Ella Xiaoyan Du¹ and Keith Betts¹, ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Real world studies comparing the healthcare utilization of anti-TNFs vs. non-TNFs as the next alternative after the failure of the first anti-TNF are scarce.…
Abstract Number: 555 • 2015 ACR/ARHP Annual Meeting
Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis
Douglas C. Wolf¹, Martha Skup², Hongbo Yang³, Elizabeth Faust³, Jenny Griffith², Jingdong Chao² and Mark Lebwohl⁴, ¹Atlanta Gastroenterology Associates, Atlanta, GA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Mount Sinai Medical Center, New York, NY
Background/Purpose: Patients with RA are often treated with anti-tumor necrosis factor (TNF) agents. However, patients with a stable response to anti-TNF therapy may discontinue or…
Abstract Number: 598 • 2015 ACR/ARHP Annual Meeting
Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre¹, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Xabier Barber³, Ana Pons⁴, Catalina Cano⁴, Marisa Lorente⁵ and Juan Molina⁶, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ³Centro de Investigación Operativa, Miguel Hernández University, Elche, Spain, ⁴Hospital Marina Baixa, Nursing, Villajoyosa, Spain, ⁵Marina Baixa Hospital, Nursing, Villajoyosa, Spain, ⁶Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain
Background/Purpose: To evaluate the economic impact of adalimumab (ADL) and etanercept (ETN) dose reduction (by decreasing treatment frequency) and drug monitoring in patients with rheumatoid…
Abstract Number: 989 • 2015 ACR/ARHP Annual Meeting
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis
Megan Barber¹, John G. Hanly², Aidan O'Keeffe³, Li Su⁴, Murray Urowitz^5,6, Yvan St. Pierre⁷, Juanita Romero-Diaz⁸, C. Gordon⁹, Sang-Cheol Bae¹⁰, Sasha Bernatsky¹¹, Daniel J Wallace¹², Joan T. Merrill¹³, David A. Isenberg¹⁴, Anisur Rahman¹⁵, Ellen M. Ginzler¹⁶, Paul R. Fortin¹⁷, Dafna D. Gladman¹⁸, Jorge Sanchez-Guerrero¹⁹, Michelle Petri²⁰, Ian N. Bruce²¹, Mary Anne Dooley²², Rosalind Ramsey-Goldman²³, Cynthia Aranow²⁴, Graciela S. Alarcon²⁵, W. Winn Chatham²⁶, Kristján Steinsson²⁷, Ola Nived²⁸, Gunnar K. Sturfelt²⁹, Susan Manzi³⁰, Munther Khamashta³¹, Ronald F. van Vollenhoven³², Asad Zoma³³, Manel Ramos-Casals³⁴, Guillermo Ruiz-Irastorza³⁵, S. Sam Lim³⁶, Thomas Stoll³⁷, Murat Inanc³⁸, Kenneth C. Kalunian³⁹, Diane L. Kamen⁴⁰, Peter Maddison⁴¹, Christine A. Peschken⁴², Søren Jacobsen⁴³, Anca Askanase⁴⁴, Jill P. Buyon⁴⁵, Chris Theriault⁴⁶, Kara Thompson⁴⁶, Vernon Farewell⁴⁷ and Ann E. Clarke⁴⁸, ¹Division of Rheumatology, University of Calgary, Caglary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Statistical Science, University College London, London, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico, ⁹School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁰Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ¹²Cedars-Sinai Medical Center, West Hollywood, CA, ¹³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹⁶Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁷Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁸Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²⁰Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²¹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²²UNC Kidney Centre, Chapel Hill, NC, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Feinstein Institute for Medical Research, Mahasset, NY, ²⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁶Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²⁷Centre for Rheumatology Research, Landspital University Hospital, Reykjavik, Iceland, ²⁸Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³⁰Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³¹Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³³Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Autoimmune Disease Research Unit, Service of Internal Medicine, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, ³⁶Emory University School of Medicine, Atlanta, GA, ³⁷Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³⁸Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ⁴⁰Medicine, Medical University of South Carolina, Charleston, SC, ⁴¹Musculoskeletal Medicine, Bangor University, Bangor, United Kingdom, ⁴²Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ⁴³Department of Rheumatology,, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁴⁴Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴⁶Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴⁷Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Little is known about the long-term costs of lupus nephritis (LN). The annual and long-term healthcare costs were compared between SLE patients with and…
Abstract Number: 1001 • 2015 ACR/ARHP Annual Meeting
What Is the Most Cost-Effective Physical Therapy Strategy to Treat Knee Osteoarthritis?
Allyn Bove¹, Ken Smith², Christopher Bise¹, Julie Fritz³, John Childs⁴, Gerard P. Brennan⁵, J. Haxby Abbott⁶ and G. Kelley Fitzgerald¹, ¹Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ²Division of Internal Medicine; Institute for Clinical Research Education, University of Pittsburgh, Pittsburgh, PA, ³Department of Physical Therapy, University of Utah, Salt Lake City, UT, ⁴US Army-Baylor University, Schertz, TX, ⁵Rehabilitation Services, Intermountain Healthcare, Murray, UT, ⁶Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, University of Otago, Dunedin, New Zealand
Background/Purpose: The American College of Rheumatology (ACR) strongly recommends exercise therapy as a first-line conservative treatment for individuals with knee osteoarthritis (OA).1 Evidence supporting manual…
Abstract Number: 1270 • 2015 ACR/ARHP Annual Meeting
Low Socioeconomic Status As a Predictor of Long-Term Direct Medical Costs Following Diagnosis of Granulomatosus with Polyangiitis: A General Population-Based Cohort Study
Natalie McCormick¹, Carlo Marra² and J Antonio Avina-Zubieta³, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Estimates of the healthcare costs of Granulomatosus with polyangiitis (GPA) and predictors of costs are scarce. In particular, while socioeconomic status (SES) is associated…
Abstract Number: 1295 • 2015 ACR/ARHP Annual Meeting
Online Consultation for Rheumatic Disease Patients Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Fei Xiao¹, Xiangyuan Liu², Hua Wei³, Zhijun Li⁴, Yanhong Huang⁵, Yaohu Jiang⁶, Huiqiong Zhou⁷, Jie Shen⁸, Yuhua Jia¹, Li Zhang¹, Yuan Liu¹, Minjun Wang¹ and Fengchun Zhang⁹, ¹Gothic Internet Technology Corporation, Shanghai, China, ²Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁵Beijing Jishuitan Hospital, Beijing, China, ⁶Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China, ⁷The First Affiliated Hospital of PLA General Hospital, Beijing, China, ⁸University of Rochester, Rochester, NY, ⁹Department of Rheumatology, Peking Union Medical college Hosptial, Beijing, China
Background/Purpose: China has no primary medical care and referral system. Patients can choose any hospitals or any doctors they like to seek medical care. As…
Abstract Number: 1678 • 2015 ACR/ARHP Annual Meeting
Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA?
Jonas K Eriksson¹, Martin Neovius², Johan Askling³ and ARTIS study group, ¹Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Numerous studies have modeled whether biologic drugs are good value for money in the treatment of RA, in terms of reducing health care use…
Abstract Number: 1688 • 2015 ACR/ARHP Annual Meeting
Trends in Hospitalizations and Charges for Ankylosing Spondylitis, 1993-2012
Na Lu¹, Hyon Choi² and Maureen Dubreuil^3,4, ¹Boston University School of Medicine, Boston, MA, ²Massachussetts General Hospital/Harvard Medical School, Boston, MA, ³Rheumatology, Boston VA HealthCare System, Boston, MA, ⁴Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: In the last two decades, tumor necrosis factor alpha (TNFα) inhibitors have been approved for use, and recommended as part of clinical treatment…
Abstract Number: 2160 • 2015 ACR/ARHP Annual Meeting
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study
Raashid Luqmani¹, Ellen Lee², Surjeet Singh³, Michael Gillett², Wolfgang A. Schmidt⁴, Mike Bradburn², Bhaskar Dasgupta^5,6, Andreas P Diamantopoulos⁷, Wulf Forrester-Barker⁸, William Hamilton⁹, Shauna Masters¹⁰, Brendan McDonald¹¹, Eugene McNally⁸, Colin T. Pease¹², Jennifer Piper⁸, John Salmon¹³, Allan Wailoo², Konrad Wolfe¹⁴, Andrew Hutchings¹⁵ and TABUL Study group, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ³1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁵Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁶Southend University Hospital, Essex, United Kingdom, ⁷Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁹Primary Care, University of Exeter, Exeter, United Kingdom, ¹⁰Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹¹Department of Neuropathology and Ocular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹²Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹³Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹⁴Department of Pathology, Southend University Hospital, Essex, United Kingdom, ¹⁵Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis which if untreated can lead to permanent sight loss. It is…
Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
JoAnne Foody¹, Robin Turpin², Beni Tidwell³ and Kathy Schulman⁴, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ³ORS, Shrewsbury, MA, ⁴Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
Abstract Number: 2473 • 2015 ACR/ARHP Annual Meeting
Psycho-Socio-Economic Burdens of Childhood Onset Rheumatic Diseases on Families
Sook Fun Hoh¹, Manasita Tanya², Justin Hung Tiong Tan², Lena Das^2,3 and Thaschawee Arkachaisri², ¹Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ²Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ³Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Rheumatic diseases (RD) in children, being complex and chronic in nature, do not only pose physical insult to the affected child, but also psychological…
Abstract Number: 113 • 2015 ACR/ARHP Annual Meeting
Longitudinal, Incremental Direct Medical Costs of Giant Cell Arteritis for the First Five Years Following Diagnosis: A General Population-Based Cohort Study
Natalie McCormick¹, Carlo Marra² and J Antonio Avina-Zubieta³, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Giant cell arteritis (GCA) is the most common form of adult vasculitis, but estimates of the healthcare costs of GCA are extremely scarce. We…
Abstract Number: 2781 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Adding Etanercept Vs. Sulfasalazine and Hydroxychloroquine to Methotrexate Therapy: A Randomized Noninferiority Trial
Nick Bansback¹, Ciaran Phibbs², Huiying Sun³, James R. O'Dell⁴, Mary Brophy⁵, Edward C. Keystone⁶, Sarah Leatherman⁷, Ted R. Mikuls⁴ and Aslam H. Anis³, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²Health Economics Resource Center (152), Palo Alto VA Health Care System, Menlo Park, CA, ³St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵VA Boston Heathcare System, Boston, MA, ⁶Medicine, University of Toronto, Toronto, ON, Canada, ⁷VA Boston Heatlhcare System, Boston, MA
Background/Purpose: To estimate the incremental cost-effectiveness of etanercept plus methotrexate versus a triple regimen of disease-modifying anti rheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) over 24…
Abstract Number: 2235 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Long-Term Opioid Use in the Treatment of Knee Osteoarthritis in Older Patients with Multiple Comorbidities
Jeffrey N. Katz¹, Savannah Smith², Jamie E. Collins³, Joanne M. Jordan⁴, David J. Hunter⁵, Edward H. Yelin⁶, Lisa Suter⁷, A. David Paltiel⁸ and Elena Losina³, ¹Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ²Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁵Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁶Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁷Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT, ⁸Yale School of Public Health, New Haven, CT
Background/Purpose: Because older patients with osteoarthritis (OA) and multiple comorbidities face high risk of toxicity from nonselective non-steroidal antiinflammatory drugs (NSAIDs) and Cox-2 inhibitors, opiates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].